middle.news
Neurotech Launches NTI164 Prescriber Program Amid FDA Rare Disease Nod
11:31am on Tuesday 28th of October, 2025 AEDT
•
Healthcare
Read Story
Neurotech Launches NTI164 Prescriber Program Amid FDA Rare Disease Nod
11:31am on Tuesday 28th of October, 2025 AEDT
Key Points
Initiation of NTI164 Authorised Prescriber program for controlled access
FDA grants Rare Pediatric Disease Designation for NTI164 in Rett Syndrome
Published clinical trial results demonstrate safety and efficacy of NTI164
Advancement of chronic toxicology studies and IND application preparation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE